Trial Profile

Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esketamine (Primary)
Indications Tinnitus
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms TACTT2
Sponsors Altamira Therapeutics; Auris Medical

Most Recent Events

13 Mar 2018 According to an Auris Medical media release, the Company is investigating the outcomes and will provide an update in due course.
26 Feb 2018 According to Auris Medical media release, Elias Michaelides, MD (Yale School of Medicine) participated as the principal investigator for this trial.
01 Sep 2017 Results assessing safety and tolerability of repeated intratympanic administration of the gel-formulated NMDA receptor antagonist AM-101 in acute patients with inner ear tinnitus, were published in the Otolaryngology - Head and Neck Surgery.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com